The cytochrome p450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease by Schuck, RN et al.
The Cytochrome P450 Epoxygenase Pathway Regulates
the Hepatic Inflammatory Response in Fatty Liver
Disease
Robert N. Schuck1, Weibin Zha1, Matthew L. Edin2, Artiom Gruzdev2, Kimberly C. Vendrov1,
Tricia M. Miller3, Zhenghong Xu4, Fred B. Lih2, Laura M. DeGraff2, Kenneth B. Tomer2, H. Michael Jones5,
Liza Makowski6, Leaf Huang4, Samuel M. Poloyac3, Darryl C. Zeldin2, Craig R. Lee1*
1Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States of
America, 2Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina,
United States of America, 3Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America,
4Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States of America, 5Department of
Pathology and Laboratory Medicine, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America, 6Department of Nutrition,
Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, United States of America
Abstract
Fatty liver disease is an emerging public health problem without effective therapies, and chronic hepatic inflammation is a
key pathologic mediator in its progression. Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to
biologically active epoxyeicosatrienoic acids (EETs), which have potent anti-inflammatory effects. Although promoting the
effects of EETs elicits anti-inflammatory and protective effects in the cardiovascular system, the contribution of CYP-derived
EETs to the regulation of fatty liver disease-associated inflammation and injury is unknown. Using the atherogenic diet
model of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), our studies demonstrated that
induction of fatty liver disease significantly and preferentially suppresses hepatic CYP epoxygenase expression and activity,
and both hepatic and circulating levels of EETs in mice. Furthermore, mice with targeted disruption of Ephx2 (the gene
encoding soluble epoxide hydrolase) exhibited restored hepatic and circulating EET levels and a significantly attenuated
induction of hepatic inflammation and injury. Collectively, these data suggest that suppression of hepatic CYP-mediated EET
biosynthesis is an important pathological consequence of fatty liver disease-associated inflammation, and that the CYP
epoxygenase pathway is a central regulator of the hepatic inflammatory response in NAFLD/NASH. Future studies
investigating the utility of therapeutic strategies that promote the effects of CYP-derived EETs in NAFLD/NASH are
warranted.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a rapidly growing
public health problem that is prevalent in approximately 30% of
the United States general population [1]. NAFLD begins with
simple steatosis, and may progress to non-alcoholic steatohepatitis
(NASH), and ultimately to advanced fibrosis and cirrhosis of the
liver [2]. Although the progression from NAFLD to NASH is
poorly understood, the development and progression of hepatic
inflammation is a key pathological mediator in this transition and
is associated with the development of comorbid conditions [3,4].
In the early stages of NAFLD, an imbalance between uptake
and export of lipids by hepatocytes leads to lipid accumulation
within the liver. Increased hepatic saturated fatty acids and
cholesterol activate toll-like receptors (TLRs) that drive activation
of nuclear factor-kB (NF-kB)-mediated inflammatory responses
[5]. Sustained activation of the hepatic inflammatory response
drives macrophage infiltration into the liver, ultimately causing
fibrosis and hepatic injury [6]. Consistent with this pathological
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progression of NAFLD/NASH, the high-fat/high-cholesterol
‘‘atherogenic’’ diet model of steatohepatitis induces dyslipidemia,
hepatic inflammation, and fibrosis, through an innate immune-
mediated mechanism [7,8].
Arachidonic acid is metabolized by cyclooxygenases, lipoxy-
genases, and cytochromes P450 (CYP) to biologically active
eicosanoids, which are critical regulators of numerous biological
processes including inflammation [9]. CYP enzymes are abun-
dantly expressed in the liver where they catalyze the oxidative
biotransformation of xenobiotics [10]. In addition, certain CYP
isoforms metabolize endogenous substrates. Notably, CYP epox-
ygenase enzymes from the CYP2C and CYP2J subfamilies
metabolize arachidonic acid to biologically active epoxyeicosa-
trienoic acids (EETs) [11]. However, EETs are rapidly hydrolyzed
by soluble epoxide hydrolase (sEH, Ephx2) to their corresponding
dihydroxyeicosatrienoic acid (DHETs), which are generally less
biologically active [11]. Previous studies have shown that acute,
lipopolysaccharide (LPS)-evoked activation of the innate immune
response suppresses hepatic CYP epoxygenase expression and
EET biosynthesis [12]. Moreover, increased endothelial EET
biosynthesis, or decreased global sEH-mediated EET hydrolysis,
attenuates NF-kB activation and the acute vascular and systemic
inflammatory response to LPS [12,13,14].
Collectively, these studies demonstrate that hepatic EET
biosynthesis is suppressed in response to activation of the innate
immune system, and potentiation of the CYP epoxygenase
pathway attenuates innate immune-dependent acute inflammatory
responses [15]. However, the functional relevance of the CYP
epoxygenase pathway in the development and progression of
sustained, fatty liver disease-associated hepatic inflammation and
injury has not been investigated. Therefore, the objective of our
study was to 1) evaluate the impact of atherogenic diet-induced
NAFLD/NASH on hepatic CYP epoxygenase expression and
EET biosynthesis; and, 2) determine if promoting the effects of
CYP epoxygenase-derived EETs attenuates fatty liver disease-
associated hepatic inflammation and injury.
Materials and Methods
Ethics Statement
All studies were completed in accordance with the Public
Health Service Policy on Humane Care and Use of Laboratory
Animals, and were approved by the Institutional Animal Care and
Use Committee at the University of North Carolina-Chapel Hill
(UNC) and the National Institute of Environmental Health
Sciences.
Reagents
Reagents were obtained from ThermoFisher Scientific (Wal-
tham, MA) unless otherwise indicated.
Animals
All experiments were performed in adult male mice on a
C57BL/6J background that were 11–20 weeks of age at the
initiation of the experiments. Wild-type (WT) C57BL/6J mice
were purchased from Jackson Laboratory (Bar Harbor, ME). Mice
with targeted disruption of Ephx2 (Ephx22/2) were backcrossed
onto a C57BL/6J genetic background for more than 10
generations, as described [16]. All mice had free access to food
and water and were housed in temperature and humidity
controlled rooms using a 12 hour light/dark cycle.
Experimental Protocol
Mice were fed ad libitum a commercially available atherogenic
(ATH) diet [17,18] containing 40% kilocalories from fat, 1.25%
cholesterol and 0.5% cholic acid (D12109c, Research Diets Inc.,
New Brunswick, NJ) or a standard chow (STD) diet containing
14% kilocalories from fat and 0.02% cholesterol (ProLab RMH
3000, PMI Nutrition International, Brentwood, MO). An initial
time-course experiment was conducted to assess the relative
induction of hepatic inflammation and injury following two, four,
or eight weeks of atherogenic diet administration. All subsequent
studies were conducted over four weeks.
The first series of experiments evaluated the effect of
atherogenic diet feeding on hepatic CYP epoxygenase expression
and EET biosynthesis in WT mice (Jackson Laboratory). The
second series of experiments evaluated the effect of disruption of
sEH-mediated EET hydrolysis on atherogenic diet induced
hepatic inflammation and injury in Ephx22/2 and corresponding
WT control mice. At the termination of each experiment, mice
were euthanized by CO2 asphyxiation. Blood was collected via
cardiac puncture, and plasma was separated by centrifugation.
Liver tissue was harvested; one part was snap-frozen in liquid
nitrogen and stored at 280uC pending analysis, while the
Figure 1. Plasma and hepatic lipid levels increase in response to atherogenic diet administration. (A) Plasma total cholesterol levels, (B)
liver total cholesterol levels, and (C) liver triglyceride levels were significantly higher in mice administered the atherogenic diet for 4 weeks compared
to mice administered the STD diet (STD diet: n = 6–10, atherogenic diet: n = 13–22). *P,0.05 vs. STD diet group.
doi:10.1371/journal.pone.0110162.g001
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remainder was fixed in 4% paraformaldehyde and embedded in
paraffin for histological analysis.
Hydrodynamic Delivery of Ephx2 to Ephx22/2 Mice
In order to characterize the contribution of hepatic sEH to
circulating EET levels in vivo, the hydrodynamic injection-based
transfection method was utilized to restore hepatic Ephx2
expression in Ephx22/2 mice. In this well-characterized method,
a large volume of plasmid DNA is rapidly injected into the tail vein
to markedly increase hydrostatic pressure in the inferior vena cava
and preferentially drive transgene delivery to the liver [19,20].
The murine Ephx2 (NM_007940) cDNA was PCR amplified
with specific forward (59-ATGGCGCTGCGTGTAGCC-39) and
reverse (39-CTAAATCTTGGAGGTCAC-59) primers from
whole liver total cDNA, subcloned into the pcDNA3.1(–)
expression vector (Invitrogen, Carlsbad, CA, USA) downstream
of the cytomegalovirus (CMV) enhancer-promoter, and then
confirmed by sequencing. Ephx22/2 mice received 0.75 mg/kg of
plasmid DNA (pcDNA3.1-Ephx2 or empty pcDNA3.1 vector
[control], n = 4 per group) in phosphate buffered saline (PBS) by
tail vein injection. The injection volume was 9% of the body
weight (22.5 mg plasmid delivered in 2.7 mL PBS per 30 gram
mouse), and the injection time was 5 seconds, as described
[19,20,21]. After 18 hours, the mice were euthanized by CO2
asphyxiation, and plasma and liver tissue were harvested and
stored at 280uC pending analysis.
Direct Quantification of CYP-Derived Eicosanoids in
Plasma and Liver
Arachidonic acid metabolites from the CYP epoxygenase
pathway (8,9-EET, 11,12-EET, 14,15-EET, 5,6-DHET, 8,9-
DHET, 11,12-DHET, 14,15-DHET) and CYP v-hydroxylase
pathway (20-hydroxyeicosatetraenoic acid [HETE]) were extract-
ed from plasma and liver and then quantified by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) as
previously described, with minor modifications [22]. Briefly,
plasma (200 uL) was diluted in 250 uL of a 0.1% acetic acid/
5% methanol solution containing 0.009 mM butylated hydro-
xytoluene (BHT), spiked with internal standards (3 ng each of
PGE2-d4, 10,11-DiHN, and 10,11-EpHep; Cayman Chemical,
Ann Arbor, MI), and then underwent solid-phase extraction, as
described [22]. Following serial passage through HyperSep Retain
SPE columns (Thermo Scientific, Bellefonte, PA, USA), the
columns were washed and then eluted with 0.5 mL of methanol
and 1 mL of ethyl acetate into glass tubes with 10 mL of trapping
solution (30% glycerol in methanol). Liver tissue (approximately
20 mg) was weighed and homogenized in 0.1% acetic acid/5%
methanol solution containing 0.009 mM BHT and 100 mM (5%
Figure 2. Hepatic expression of arachidonic acid metabolism pathway genes in response to atherogenic diet administration. Gene
expression profiling was completed in liver using the Agilent Whole Mouse Genome Microarray (n = 4 per group). To generate the enrichment plot,
each gene on the microarray is rank-ordered (left to right) according to its correlation with atherogenic diet administration (most positive on the far
left, most negative on the far right). The enrichment plot for the arachidonic acid metabolism pathway gene set enrichment analysis (GSEA) indicates
the position of each gene (vertical lines) within the pathway in the overall rank-order of the correlation (top of figure). The p-value for the GSEA is
provided. A heat-map is provided illustrating gene expression levels for each gene in the core enrichment subset (bottom of figure). Blue indicates
the gene is down-regulated and red indicates the gene is up-regulated. CYP epoxygenase genes from the Cyp2c and Cyp2j subfamilies are denoted
in blue.
doi:10.1371/journal.pone.0110162.g002
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w/v) of the sEH inhibitor trans-4-[4-(3-adamantan-1-ylureido)-
cyclohexyloxy]-benzoic acid (t-AUCB, kindly provided by Dr.
Bruce Hammock, University of California-Davis), spiked with the
internal standards, and then underwent liquid-liquid extraction.
Liver lysates were vortexed with 2 mL of ethyl acetate (twice) for
10 minutes, and the organic layers were transferred to a single
glass collection tube containing 6 uL of 30% glycerol. Plasma and
liver extracts were dried under nitrogen gas, purged with argon
gas, and then stored at -80uC pending analysis.
Following reconstitution in 50 uL of 30% ethanol, online liquid
chromatography of extracted samples was performed with an
Agilent 1200 Series capillary HPLC (Agilent Technologies, Santa
Clara, CA). Separations were achieved using a Halo C18 column
(2.7 mm, 10062.1 mm; MAC-MOD Analytical, Chadds Ford,
PA), which was held at 50uC and a flow rate of 400 ml/min.
Mobile phase A was 0.1% acetic acid in 85:15 water:acetonitrile.
Mobile phase B was 0.1% acetic acid in acetonitrile. Gradient
elution was used and the mobile phase was varied as follows: 20%
B at 0 min, ramp from 0 to 5 min to 40% B, ramp from 5 to
7 min to 55% B, ramp from 7 to 13 min to 64% B. From 13 to
19 min the column was flushed with 100% B at a flow rate of
550 ml/min before being returned to starting conditions and
equilibrated for 6 minutes. Samples were solvated in 50 ml of 30%
ethanol and injected in triplicate at 10 ml per injection.
Electrospray ionization tandem mass spectrometry was used for
detection. Analyses were performed on an MDS Sciex API 3000
equipped with a TurboIonSpray source (Applied Biosystems,
Foster City, CA). Turbo desolvation gas was heated to 425uC at a
flow rate of 6 L/min. All analytes were monitored simultaneously
in a scheduled multiple reaction monitoring experiment as
negative ions at parent ion-product ion mass/charge ratio pairs
and retention times. The relative response ratios of each analyte
were used to calculate concentrations, while correcting for
surrogate losses via quantification relative to internal standards.
Liver eicosanoid concentrations were normalized to tissue weight,
the 14,15-EET:DHET ratio was calculated as an in vivo
biomarker of sEH metabolic function [16], and the sum of EET
levels (8, 9-, 11, 12–14, 15-EET) were calculated as a biomarker of
CYP epoxygenase pathway function [23].
Formation of CYP-Derived Eicosanoids in Liver
Microsomes
Microsomal fractions were isolated from hepatic tissue as
previously described [12] and microsome protein concentrations
were determined using the BCA method [24]. Microsomal protein
was incubated with 50 mM arachidonic acid in 1 mL of a 0.12 M
potassium phosphate incubation buffer containing 5 mM MgCl
[12], and incubations were completed at 37uC for 20 minutes;
reactions were initiated by adding 1 mM NADPH and terminated
by placing the samples on ice. Incubations were completed in the
presence of 5 mM of t-AUCB to minimize EET hydrolysis.
Following termination of the reaction samples were diluted 10-
fold, internal standard (20-HETE-d6) was added and metabolites
were extracted, dried under a stream of nitrogen gas and
reconstituted for analysis. Metabolites of arachidonic acid were
then quantified by LC-MS/MS, as described [12]. The incuba-
tions were performed under saturating concentrations of arachi-
donic acid, where formation rates reflect the amount of
Figure 3. Atherogenic diet administration suppresses the CYP epoxygenase pathway. (A) Plasma sum EET levels and (B) liver sum EET
levels were significantly lower in mice administered the atherogenic diet compared to mice administered the STD diet (n = 4–6 per group). (C) The
EET formation rate in the presence of saturating arachidonic acid concentrations was also suppressed in liver microsomes isolated from mice
administered the atherogenic diet compared to mice administered the STD chow diet (n = 8 per group). (D) Liver Cyp2c29, Cyp2c50, Cyp2c55, and
Cyp2j5 mRNA levels were significantly suppressed but (E) Ephx2 mRNA levels were not significantly different (STD diet: n = 6, atherogenic diet n = 5).
*P,0.05 vs. STD diet group.
doi:10.1371/journal.pone.0110162.g003
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biologically active protein and significantly correlate with CYP
mRNA and protein levels [12,25].
Hepatic Microarray and Gene Set Enrichment Analysis
Total RNA was isolated from homogenized liver (n = 4 per
group) using the RNeasy mini-prep kit (Qiagen, Valencia, CA).
Global gene expression analysis was conducted using the Agilent
Whole Mouse Genome 4644 multiplex array (Agilent Technol-
ogies, Inc., Santa Clara, CA) according to the manufacturer’s
protocol. Briefly, 1.65 micrograms of Cy3 labeled cRNAs were
fragmented and hybridized for 17 hours in a rotating hybridization
oven. Slides were then washed and scanned, data were acquired
using the Agilent Feature Extraction software version 9.5 (Agilent
Technologies) using 1-color defaults for all parameters. The
resulting data were processed and analyzed using Genespring
version 12.1 (Agilent Technologies). Only probes flagged ‘‘detect-
ed’’ in at least 75% of samples from at least one treatment group
were included, resulting in 31,643 probes in the final dataset.
Datasets were deposited with the Gene Expression Omnibus of the
National Center for Biotechnology Information (GEO Series
accession number GSE53381).
Gene set enrichment analysis (GSEA) Version 2.0 was used to
determine if the arachidonic acid metabolism pathway is enriched
in WT mice administered the atherogenic compared to WT mice
administered the standard diet. Genes involved in the metabolism
of arachidonic acid to biologically active eicosanoids were
identified using the Kyoto Encyclopedia of Genes and Genomes
(KEGG) [26] ‘arachidonic acid metabolism pathway’ for mice
(map00590), and limited to genes involved in arachidonic acid
liberation from the cell membrane and metabolism.
Analysis of variance (ANOVA) with unequal variance was used
to generate the complete list of genes significantly up-regulated or
down-regulated in response to the atherogenic diet at a false
discovery rate (Benjamini-Hochberg) of 1% using Genespring GX
(Agilent Technologies, Inc., Santa Clara, CA) (Table S1). Pathway
enrichment was determined using the National Institutes of Health
(NIH) Database for Annotation, Visualization and Integrated
Discovery (DAVID) Version 6.7, which uses a modified Fisher’s
Exact Test to calculate an ‘‘Enrichment Score’’ for each functional
annotation cluster and identifies enriched biological themes
without a pre-specified hypothesis [27,28]. Biological Process
Terms and Molecular Function Terms were included as Gene
Ontologies, and the Classification Stringency was set to high; all
other default parameters were unchanged. The list of significantly
up-regulated or down-regulated genes was uploaded to DAVID
and compared to the mus musculus reference to generate a list of
functional pathways that were over-represented in response to
atherogenic diet feeding. P-values were calculated by computing
102Enrichment Score, with p,0.01 (Enrichment Score .2) consid-
ered statistically significant.
Biochemical Analysis
Plasma total cholesterol and alanine aminotransferase (ALT)
levels were quantified using a Vitros 350 automated chemical
analyzer (Ortho-Clinical Diagnostics, Rochester, NY). Total
cholesterol and triglyceride levels were quantified in homogenized
liver tissue using the Biovision Cholesterol Ester Quantification
Figure 4. Hydrodynamic delivery of Ephx2 to Ephx22/2mice. Ephx22/2mice were administered plasmid DNA (empty vector [control] or vector
containing murine Ephx2) by hydrodynamic injection (9% of body weight over 5 seconds). All mice were fed with a standard chow diet, and liver
tissue and plasma were harvested 18 hours following injection. A parallel group of untreated WT and Ephx22/2 mice were included for comparison
(n = 4 per group). (A) A representative immunoblot in liver lysates and (B) corresponding densitometry analysis demonstrate partial restoration of
hepatic sEH protein expression in Ephx22/2 mice. (C) Quantitative RT-PCR demonstrates partial restoration of Ephx2 mRNA levels in liver. (D) In
contrast, no detectable increase in Ephx2 mRNA levels was observed in either kidney or heart tissue. (E) Hydrodynamic delivery of Ephx2 significantly
lowered the plasma 14,15-EET:DHET ratio (biomarker of sEH metabolic function [lower ratio indicative of higher function]) to a level equivalent with
untreated WT mice. Hydrodynamic injection of empty vector markedly increased (F) hepatic Ccl2 mRNA levels and (G) plasma ALT levels compared to
untreated controls, and induction of these biomarkers of hepatic inflammation and injury were significantly increased in the presence of the Ephx2
transgene. *P,0.05 vs. Ephx22/2 (vector) control.
doi:10.1371/journal.pone.0110162.g004
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Kit II and the Biovision Triglyceride quantification Kit, respec-
tively, according to the manufacturer’s instructions (Biovision
Incorporated, Milpitas, CA).
Quantitative RT-PCR
Quantitative RT-PCR was performed in triplicate using the
ABI 7300 Real-Time PCR system, as described [12]. Expression
of hepatic Tlr4 (Mm00445274_m1), Cyp2c29 (Mm00725580_s1),
Cyp2c50 (Mm00663066_gH), Cyp2c55 (Mm00472168_m1),
Cyp2j5 (Mm00487292_m1), Ephx2 (Mm01313813_m1), Tnfa
(Mm00443258_m1), Ccl2 (Mm00441242_m1), Nfkb1
(Mm00476361_m1) and Col3a1 (Mm01254476_m1) was quanti-
fied using Taqman Assays on Demand (Applied Biosystems),
normalized to Gapdh (endogenous control, Mm99999915_g1) and
expressed relative to the control group using the 22DDCt method
[29].
ELISA
Liver tissue was homogenized in lysis buffer (50 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X, 1 mM
NaF, 0.25% Na deoxycholate and protease inhibitors) and the S9
fraction was separated by centrifugation. Protein concentrations of
the homogenate were quantified using the BCA method [24].
Monocyte chemoattractant protein-1 (MCP-1), and vascular
cellular adhesion molecule-1 (VCAM-1) protein levels were
quantified in liver homogenates using the mouse CCL2/JE/
MCP-1 and VCAM-1/CD106 Quantikine ELISA kits (R&D
Systems, Minneapolis, MN, USA), respectively, after loading equal
amounts of protein into each well. Concentrations were normal-
ized to mg of liver protein. Plasma concentrations of MCP-1 were
quantified using the mouse CCL2/JE/MCP-1 Quantikine ELISA
kit (R&D Systems) following a four-fold dilution.
Immunoblotting
Liver homogenates (30 mg protein) were separated by 10%
NuPAGE Bis-Tris gels, and then transferred to nitrocellulose
membranes (Invitrogen). Membranes were blocked in 5% non-fat
milk in Tris-buffered saline (TBS), washed, and then incubated
with either anti-phospho-IkBa (1:500 in 1% BSA in TBS with
0.05% Tween 20; #2859, Cell Signaling Technology, Danvers,
MA, USA), anti-sEH (1:1000 in 5% milk in TBS with 0.1%
Tween 20; sc22344, Santa Cruz Biotechnology, Santa Cruz, CA),
or anti-GAPDH (1:1000 in 5% BSA in TBS with 0.05% Tween
20; #2118, Cell Signaling) antibodies, washed and then incubated
with the appropriate horseradish peroxidase-conjugated secondary
antibody (Santa Cruz Biotechnology), as described [12]. Immu-
noreactive bands were detected by chemiluminescence using the
ECL Western Blotting Substrate (Thermo Scientific, Rockford,
IL). The density of the immunoreactive phospho-IkBa bands,
normalized to GAPDH, was quantified using ImageJ software
(NIH) as a biomarker of NF-kB activation, as described [12].
Histology and Immunohistochemistry
Liver tissue (left lobe) was fixed in 4% paraformaldehyde for 24
hours, processed, embedded in paraffin, and then sectioned using
a serial interrupted technique (5 mm sections, 200 mm apart).
Figure 5. Genetic disruption of sEH-mediated EET hydrolysis increases circulating and hepatic EET levels. Plasma (n = 10–19 per group)
and liver (n = 3–5 per group) eicosanoids were quantified in wild-type (WT) mice fed the STD diet and WT and Ephx22/2 mice fed the atherogenic
diet. (A) Plasma and (C) hepatic 14,15-EET:DHET ratios (biomarker of sEH metabolic function [lower ratio indicative of higher function]) and (B) plasma
and (D) hepatic sum EET levels were significantly higher in atherogenic diet fed Ephx22/2 compared to WT mice. (E) Liver Cyp2c29 expression (n = 10–
19 per group) was significantly suppressed in both WT and Ephx22/2 mice fed the atherogenic diet. *P,0.05 vs. WT atherogenic diet group.
doi:10.1371/journal.pone.0110162.g005
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Sections underwent hematoxylin and eosin (H&E) and immuno-
histochemical (F4/80) staining. Digital images were acquired with
the ScanScope CS slide capture device (Aperio, Vista, CA) and
analyzed using ImageScope Version 11.1 (Aperio).
Immunohistochemistry was performed by treating slides with
pH 6.0 sodium citrate buffer (Dako North America, Carpinteria,
CA) and endogenous peroxide was quenched by placing slides in a
solution of 3% H2O2 for 15 minutes. Sections were blocked using
0.25% casein in PBS (Dako North America) then incubated with a
rabbit anti-F4/80 polyclonal antibody at a 1:200 dilution (Santa
Cruz Biotechnology) followed by a goat anti-rabbit secondary
antibody at a 1:500 dilution (Jackson Immunoresearch, West
Grove, PA). Antibody binding was detected using Vectastain Elite
ABC Kit (Vector Laboratories, Burlingame, CA) and visualization
was performed with 3,3-diaminobenzidine. Sections were then
counterstained with hematoxylin, dehydrated, and mounted.
Macrophage infiltration was quantified by counting the number
of inflammatory foci (i.e., the number of macrophage clusters) per
10x field, as described [30]. All analyses were performed in
duplicate by the same individual who was blinded to treatment
group. Three non-overlapping fields were analyzed across three
sections; the number of foci were then summed and averaged to
obtain an estimate for each mouse.
The presence and extent of NAFLD was evaluated on
hematoxylin and eosin (H&E) stained slides according to a
standardized and well-established histological scoring system
(NAFLD Activity Score) that evaluates the presence and severity
of steatosis, lobular inflammation, hepatocyte ballooning, and
fibrosis [31]. Lobular inflammation, which is the most relevant
histological consequence of the atherogenic diet [8], was graded in
blinded fashion by a pathologist (H.M.J.) according to the number
of inflammatory infiltrates per 200x field as follows: 0 (no
infiltrates); 1 (,2 infiltrates per field); 2 (2–4 infiltrates per field);
and 3 (.4 infiltrates per field).
Statistical Analysis
Data were normalized to the atherogenic diet treated WT
control group and pooled across experiments, unless otherwise
indicated, and expressed as mean 6 standard error of the mean
(SEM). For continuous variables, rank-transformed mean values
were compared across diet and genotype groups using a one-way
ANOVA followed by Fisher’s LSD post hoc test with p,0.05
considered statistically significant. Lobular inflammation score (0,
1, 2, or 3) was compared across groups by Chi-squared test with a
post-hoc ordinal logistic regression analysis. Correlation between
continuous variables was evaluated using Spearman’s rank
correlation. All statistical analyses were performed using SAS
version 9.3 (SAS Institute, Cary, NC).
Results
Characterization of the Atherogenic Diet Model of
NAFLD/NASH
We first conducted a time-course experiment to characterize the
effects of atherogenic diet administration over time. Atherogenic
diet administration for two, four or eight weeks significantly
increased hepatic Ccl2 mRNA levels (MCP-1, a chemokine that
recruits monocytes; 3.060.9-, 10.964.1-, and 7.962.7-fold,
Figure 6. Genetic disruption of sEH attenuates atherogenic diet-induced hepatic expression of inflammatory biomarkers. The
atherogenic diet evoked induction of (A) plasma MCP-1, (B) liver MCP-1, and (C) liver VCAM-1 protein levels was significantly attenuated in Ephx22/2
mice (WT STD diet: n = 15–16, WT atherogenic diet: n = 37–40, Ephx22/2 atherogenic diet: n = 22–24). (D) A representative immunoblot characterizing
protein expression of phosphorylated IkB-a and GAPDH in liver lysates is provided. (E) Densitometry analysis demonstrated that the atherogenic diet-
induced increase in phosphorylated IkB-a expression, normalized to GAPDH, was attenuated in Ephx22/2 mice (n = 4–6 per group). Data are
expressed relative to the WT atherogenic diet group. *P,0.05 vs. WT atherogenic diet group.
doi:10.1371/journal.pone.0110162.g006
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Figure 7. Genetic disruption of sEH attenuates hepatic inflammation and injury. Representative (A) F4/80 (10x, scale bar = 200 mm) and (C)
H&E stained (20x, scale bar = 100 mm) images are provided. The atherogenic (ATH) diet induced increase in the (B) number of inflammatory foci per
10x field and (D) lobular inflammation score expressed as a continuous variable was significantly attenuated in Ephx22/2 mice (WT STD diet: n = 11–
12, WT ATH diet: n = 30–31, Ephx22/2 ATH diet: n = 18–19). (E) Induction of plasma ALT levels (WT STD diet: n = 10, WT ATH diet: n = 21, Ephx22/2 ATH
diet: n = 14) and hepatic collagen (type III, Col3a1) expression (WT STD diet: n = 5, WT ATH diet: n = 15, Ephx22/2 ATH diet: n = 10) by the ATH diet
were significantly attenuated in Ephx22/2 mice. *P,0.05 vs. WT ATH diet group.
doi:10.1371/journal.pone.0110162.g007
Table 1. Hepatic lobular inflammation scores.
Lobular Inflammation Score (0–3)
Group 0 1 2 3
Standard Diet
WT (control) 11 (100%) 0 (0%) 0 (0%) 0 (0%)
Atherogenic Diet
WT 9 (30%) 7 (23%) 7 (23%) 7 (23%)
Ephx22/2 12 (63%) 4 (21%) 2 (11%) 1 (2%) p = 0.034a
Data presented as the n (percentage) of mice from each group having an inflammation score of 0, 1, 2, or 3. The percentages may not equal 100% due to rounding.
aP-value for the ordinal logistic regression analysis evaluating the impact of genotype (Ephx22/2 vs. WT) on lobular inflammation score (coded as an ordinal variable: 0,
1, 2, 3) in mice administered the atherogenic diet.
doi:10.1371/journal.pone.0110162.t001
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respectively) and plasma ALT levels (a biomarker of hepatocellular
injury; 3.660.5-, 4.060.5- and 2.960.3-fold, respectively) com-
pared to the standard chow diet (p,0.005 for each comparison).
Since hepatic inflammation and injury were not further increased
at eight weeks, the four-week time-point was utilized for all follow-
up studies.
At four weeks, plasma total cholesterol, hepatic total cholesterol,
and hepatic triglyceride levels were significantly higher in mice
administered the atherogenic diet compared to mice administered
the standard chow diet (Figure 1). Body weight did not change
significantly from baseline (20.260.2 grams, p = 0.397) in
response to the atherogenic diet; however, mice administered
the standard diet experienced modest weight gain (1.260.2 grams,
p,0.001). Collectively, these data demonstrate that the athero-
genic diet model induces hepatic lipid accumulation, inflamma-
tion, and injury, which are key drivers of the development and
progression of NAFLD/NASH, independent of weight gain.
Differential Hepatic Expression of Arachidonic Acid
Metabolism Pathway Genes
We subsequently sought to determine whether the arachidonic
acid metabolism pathway was differentially expressed in liver tissue
in WT mice administered the atherogenic diet. Of the 82 genes in
the arachidonic acid metabolism pathway, 67 (82%) were included
on the microarray and passed our quality control standards.
GSEA demonstrated that the arachidonic acid metabolism
pathway was significantly enriched in mice administered the
atherogenic diet (p,0.001). Moreover, the core enrichment
subset, which is the subset of genes accounting for the observed
signal, was down-regulated in mice administered the atherogenic
diet compared to mice administered the standard chow diet
(Figure 2), indicating that relative to global hepatic gene expres-
sion changes, the arachidonic acid metabolism pathway was
suppressed in liver following atherogenic diet administration.
Notably, 22 of the 28 (79%) genes included in the core enrichment
subset were CYP transcripts, and 10 of the 22 CYPs (46%) were
CYP epoxygenases from the Cyp2c and Cyp2j subfamilies. In
parallel, biological pathway enrichment was quantified using the
full list of genes that were significantly up-regulated or down-
regulated in liver by atherogenic diet feeding in order to identify
enriched biological themes without a pre-specified hypothesis.
Consistent with the GSEA results, the ‘‘cytochrome P450’’ cluster
was among the most significantly enriched pathways (Table S2).
Dysregulation of Cytochrome P450-Mediated Eicosanoid
Metabolism
In order to specifically investigate the functional effects of fatty
liver disease-associated inflammation on CYP-mediated eicosa-
noid metabolism, we subsequently quantified plasma and hepatic
eicosanoid levels and eicosanoid formation rates in liver micro-
somes. Atherogenic diet administration significantly decreased
plasma and liver EET levels in vivo (Figure 3A and 3B), which
were highly correlated (rs = 0.817, p= 0.007). In addition, hepatic
sum EET formation ex vivo was significantly suppressed in
microsomes isolated from mice fed the atherogenic diet (Fig-
ure 3C). A similar suppression of the individual 8,9-, 11,12-, and
14,15-EET regioisomers in vivo and ex vivo was observed in
atherogenic diet fed mice (Figure S1). Consistent with suppression
of hepatic CYP epoxygenase metabolic activity, liver Cyp2c29,
Cyp2c50, Cyp2c55, and Cyp2j5 mRNA levels were all significantly
suppressed in mice administered the atherogenic diet (Figure 3D).
In contrast, no significant differences in hepatic Ephx2 mRNA
levels (Figure 3E) were observed. Furthermore, disparate effects on
the expression of Cyp4a and Cyp4f isoforms in liver were
observed, with certain isoforms either suppressed, unchanged or
induced in response to the atherogenic diet (Figure S2).
Consequently, atherogenic diet administration did not significantly
impact CYP v-hydroxylase pathway metabolic function, such that
plasma 20-HETE levels (1.560.3 vs. 1.360.2 ng/ml, p = 0.825),
liver 20-HETE levels (4.160.3 vs. 3.460.4 ng/g, p = 0.218) and
liver microsome 20-HETE formation rates (375627 vs. 338625
pmol/mg protein/minute, p = 0.689) were similar in mice fed the
standard and atherogenic diets, respectively. Collectively, these
data suggest that induction of fatty liver disease-associated
inflammation dysregulates the arachidonic acid metabolism
pathway by preferentially suppressing hepatic CYP epoxygenase
metabolic function and hepatic and systemic EET levels.
Furthermore, consistent with activation of the innate immune-
mediated inflammatory response and suppression of the CYP
epoxygenase pathway, a significant inverse correlation between
sum EET concentrations in liver tissue and hepatic Tlr4 (rs =2
0.646, p = 0.032), Nfkb1 (rs =20.746, p = 0.009), and Tnfa
(rs =20.736, p = 0.010) mRNA levels was observed. Similar
inverse correlations were observed with hepatic Cyp2c29,
Cyp2c50, Cyp2c55, and Cyp2j5 mRNA levels (Table S3).
Hydrodynamic Delivery of Ephx2 to Ephx22/2 Mice
Due to the strong correlation between hepatic and circulating
EET levels, we also sought to characterize the functional
contribution of hepatic sEH to circulating EET levels in vivo.
Delivery of plasmid DNA containing murine Ephx2 using the
hydrodynamic injection-based transfection method elicited partial
restoration of hepatic Ephx2 mRNA (Figure 4C) and hepatic sEH
protein levels (Figure 4A and 4B) to Ephx22/2 mice. In contrast,
no detectable increase in renal or myocardial Ephx2 mRNA levels
was observed (Figure 4D). Consistent with disruption of sEH-
mediated EET hydrolysis, the plasma 14,15-EET:DHET ratio was
significantly higher in Ephx22/2 (1.5260.21) compared to WT
mice (0.1660.01) under basal, standard diet fed conditions (p,
0.001). Hydrodynamic delivery of Ephx2 to Ephx22/2 mice,
however, significantly lowered the plasma 14,15-EET:DHET ratio
to a level comparable with untreated WT mice (Figure 4E),
demonstrating that hepatic sEH is a major contributor to
circulating EET levels.
Furthermore, due to the rapid increase in intravascular volume
and pressure, the hydrodynamic injection procedure also elicits
acute but transient hepatic inflammation and injury that resolves
within 24–48 hours [21]. No significant differences in either
hepatic MCP-1 expression (p =NS) or plasma ALT levels (p =NS)
were observed between Ephx22/2 and WT mice under basal,
standard diet fed conditions (Figure 4F and 4G). However, the
acute induction of hepatic MCP-1 (Figure 4F) and plasma ALT
levels (Figure 4G) elicited by the hydrodynamic injection was
exacerbated in the presence of Ephx2 transgene expression,
suggesting a functional contribution of sEH to the induction of
hepatic inflammation and injury.
Atherogenic Diet Evoked Hepatic Inflammation and
Injury in Ephx22/2 Mice
In order to evaluate the functional contribution of the CYP
epoxygenase pathway to the regulation of fatty liver disease-
associated hepatic inflammation and injury, we administered the
atherogenic diet to Ephx22/2 mice. Consistent with global
disruption of sEH-mediated EET hydrolysis, the 14,15-EET:D-
HET ratio and the sum levels of EETs were significantly higher in
atherogenic diet fed Ephx22/2 compared to atherogenic diet fed
WT mice in both plasma and liver (Figure 5A–D). Similar results
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were observed across the individual EET regioisomers and the
11,12-EET:DHET and 8,9-EET:DHET ratios in both plasma and
liver (Table S4). However, Ephx2 disruption did not influence the
atherogenic diet-evoked suppression of CYP epoxygenase expres-
sion (Figure 5E, Table S4).
In order to characterize the effects of Ephx2 disruption on
systemic and hepatic cholesterol levels, we first quantified plasma
and liver total cholesterol levels, which were significantly increased
in response to atherogenic diet administration (p,0.001 vs.
standard diet). However, plasma (21865 vs. 22366 mg/dL,
p= 0.533) and liver (4.060.4 vs. 4.260.1, p = 0.350) total
cholesterol levels were similar in atherogenic diet fed Ephx22/2
compared to WT mice.
We next evaluated expression of key inflammatory mediators in
WT and Ephx22/2 mice. Compared to the standard chow diet,
administration of the atherogenic diet significantly increased
plasma MCP-1, hepatic MCP-1, and hepatic VCAM-1 protein
levels (Figure 6A–C). The induction of chemokine and cellular
adhesion molecule expression, however, was significantly attenu-
ated in the Ephx22/2 mice. The atherogenic diet-evoked
induction of NF-kB activation in liver tissue was also significantly
attenuated in Ephx22/2 mice (Figure 6D and 6E). Furthermore,
WT mice fed the atherogenic diet exhibited significant infiltration
of macrophages into liver tissue compared to standard diet fed
mice (Figure 7A and 7B); however, macrophage infiltration was
significantly attenuated in the Ephx22/2 mice.
We further assessed the pathological severity of NAFLD/NASH
through histological evaluation of lobular inflammation [31].
Lobular inflammation was absent in all mice fed the standard diet
and present in the vast majority of WT mice administered the
atherogenic diet (Table 1). The atherogenic diet group had a
significantly higher inflammation score compared to the standard
diet group, and Ephx22/2 mice had significantly lower inflam-
mation scores compared to WT mice fed the atherogenic diet
(Figure 7C and 7D). An ordinal logistic regression analysis
confirmed that lobular inflammation scores were significantly
lower in Ephx22/2 compared to WT mice administered the
atherogenic diet (Table 1). Furthermore, induction of plasma ALT
levels, a biomarker of hepatic injury and necrosis, and hepatic
collagen (type III) expression, an early biomarker of collagen
deposition, were significantly attenuated in Ephx22/2 compared to
WT mice (Figure 7E and 7F).
Discussion
Fatty liver disease is a rapidly growing public health problem
without effective therapies that confers significant morbidity and
mortality [1], and sustained activation of the innate immune
inflammatory response is a key pathologic driver of its progression
[4]. Accumulating evidence has demonstrated that CYP-mediated
eicosanoid metabolism is an important regulator of acute and
chronic inflammatory responses, and promoting the effects of CYP
epoxygenase-derived EETs has been proposed as an anti-
inflammatory therapeutic strategy for cardiometabolic and renal
diseases [15]. However, despite the integral pathologic role of
hepatic inflammation in NAFLD/NASH and the abundance of
CYP enzyme expression in the liver, the contribution of CYP-
mediated eicosanoid metabolism to the pathogenesis and progres-
sion of this emerging public health problem remains largely
unexplored. Using the atherogenic diet model of NAFLD/NASH,
this study is the first to demonstrate that 1) induction of NAFLD/
NASH markedly and preferentially suppresses hepatic EET
biosynthesis and circulating EET levels through suppression of
hepatic CYP epoxygenase expression; and, 2) targeted disruption
of Ephx2 restores hepatic and systemic EET levels and attenuates
NAFLD/NASH-evoked hepatic inflammation and injury. Collec-
tively, these findings suggest that suppression of hepatic EET
biosynthesis is a key pathological consequence of NAFLD/NASH,
and therapeutic restoration of EET levels is an anti-inflammatory
strategy with potential utility for the treatment of fatty liver
disease-associated inflammation and injury.
It is well-established that inflammatory stimuli suppress hepatic
CYP-mediated xenobiotic metabolism [32]. In addition, we have
reported that hepatic EET biosynthesis is suppressed in an LPS
model of acute inflammation and a high-fat diet model of insulin
resistance [12,33]. Although accumulating evidence has demon-
strated that NAFLD/NASH dysregulates hepatic CYP-mediated
xenobiotic metabolism, and these effects are largely CYP isoform-
specific [34], the impact on CYP-mediated eicosanoid metabolism
has not been evaluated to date. Our expression analysis
demonstrated that, relative to global gene expression changes,
the arachidonic acid metabolism pathway is significantly dysreg-
ulated in liver following atherogenic diet administration. Notably,
these changes were largely driven by suppression of CYP
expression, including numerous Cyp2c and Cyp2j epoxygenases.
Moreover, we confirmed that atherogenic diet administration
evoked a marked suppression of hepatic Cyp2c29, Cyp2c50,
Cyp2c55, and Cyp2j5 expression, the most abundant CYP
epoxygenases in mouse liver [12]. Furthermore, EET biosynthesis
in liver microsomes and both plasma and liver EET levels were
significantly suppressed. In contrast, hepatic 20-HETE biosynthe-
sis and hepatic and plasma 20-HETE levels were not altered in
mice administered the atherogenic diet, while hepatic expression
of key Cyp4a and Cyp4f isoforms were either suppressed
(Cyp4a12, Cyp4f13), unchanged (Cyp4f15), or induced (Cyp4f16).
The disparate effects observed on hepatic CYP v-hydroxylase
expression in response to the atherogenic diet are consistent with
previous findings in acute models of inflammation [12], and
suggest that the mechanisms underlying regulation of hepatic 20-
HETE biosynthesis in the presence of inflammation are complex
and require further investigation. Collectively, these data suggest
that suppression of hepatic CYP epoxygenase-mediated EET
biosynthesis is a key pathological consequence of NAFLD/NASH.
Previous studies have demonstrated that LPS-induced inflam-
mation suppresses hepatic CYP epoxygenase expression in vivo
[12]. In addition, inflammatory cytokines including IL-1, IL-6 and
TNFa suppress CYP expression in hepatocytes, and cytokine-
mediated CYP suppression is dependent on NF-kB activation
[35]. The direct contribution of specific nuclear receptors to these
effects, however, appears to be isoform- and species-specific and
model-dependent, which suggests that upstream activation of the
innate immune response is the most important factor driving the
suppression of hepatic CYP expression. The atherogenic diet
model of NAFLD/NASH induces hepatic inflammation via an
innate immune system dependent mechanism [7,8]. Interestingly,
we observed a significant inverse correlation between Tlr4, Nfkb1,
and Tnfa expression and both hepatic CYP epoxygenase
expression and EET levels, suggesting that atherogenic diet-
evoked suppression of hepatic EET biosynthesis is most likely
mediated via activation of the innate immune response and down-
regulation of CYP epoxygenase expression. However, future
studies remain necessary to elucidate the mechanisms underlying
these effects.
Despite the abundant expression of CYP epoxygenases and sEH
in liver, the contribution of hepatic EET biosynthesis and
hydrolysis to circulating EET levels has remained unclear.
Interestingly, plasma and liver EET levels were highly correlated
in our atherogenic diet experiments. In addition, our Ephx2
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transgene delivery experiment demonstrated that restoration of
hepatic sEH expression in Ephx22/2 mice restored the plasma
14,15-EET:DHET ratio to levels similar to those observed in WT
mice. Taken together, these data suggest that EET biosynthesis
and hydrolysis in the liver is a major contributor to circulating
EET levels. The link between hepatic and plasma EET levels may
have important implications for other inflammatory diseases, as
well as the utility of circulating EET levels and the 14,15-
EET:DHET ratio as a metabolic biomarker in human studies, as
plasma EET levels and the plasma 14,15-EET:DHET ratio were
inversely correlated with circulating biomarkers of inflammation in
humans with stable coronary artery disease [36]. Although
lipidomic analyses in humans have demonstrated that NAFLD/
NASH is associated with dysregulated fatty acid metabolism, [37]
the relationship between the presence and severity of NAFLD/
NASH and altered CYP-derived eicosanoid metabolites has not
been evaluated in humans to date. Our findings demonstrate the
need, and lay the foundation, for future translational research in
this area.
It is now well-established that CYP-derived EETs have potent
anti-inflammatory effects in preclinical models of NF-kB-mediated
vascular inflammation [12,38], and also exhibit anti-apoptotic and
anti-fibrotic properties [15,39,40]; therefore, the observed sup-
pression of hepatic EET biosynthesis may propagate the inflam-
matory response and thus be detrimental in the pathological
progression of NAFLD/NASH. Although recent reports indicate
that sEH inhibition may attenuate the development of insulin
resistance and hepatic steatosis in response to a high-fat diet
[41,42], the functional contribution of the CYP epoxygenase
pathway to the regulation of NAFLD/NASH-associated hepatic
inflammation and injury had not been evaluated. We hypothesized
that decreasing sEH-mediated EET hydrolysis, by targeted
disruption of Ephx2, would restore hepatic EET levels and
attenuate atherogenic diet induced hepatic inflammation and
injury. Consistent with our hypothesis and the anti-inflammatory
effects of EETs, Ephx22/2 mice exhibited increased hepatic and
circulating EET levels and significantly attenuated NF-kB
activation, hepatic chemokine and cellular adhesion molecule
expression, macrophage infiltration into liver tissue, hepatic injury,
and collagen activation in response to atherogenic diet feeding.
Collectively, these findings demonstrate that sEH is an important
regulator of NAFLD/NASH-associated hepatic inflammation and
injury. In addition, we observed that acute hepatic inflammation
and injury evoked by the hydrodynamic injection procedure was
exacerbated in the presence of hepatic Ephx2 transgene expres-
sion, further implicating sEH as a key regulator of hepatic
inflammation and injury.
Although the atherogenic diet model of NAFLD/NASH
increases circulating and hepatic cholesterol levels, increases
hepatic triglycerides, activates the innate immune system, and
induces hepatic inflammation and injury within four weeks, these
effects are not driven by weight gain or systemic insulin resistance.
Thus, the atherogenic diet has limitations as a model of human
NAFLD/NASH, where the most common underlying etiology is
chronic obesity and insulin resistance. However, due to the known
insulin sensitizing effects of sEH inhibition [41,42], use of the
atherogenic diet model allowed us to evaluate the fundamental
pathological role of hepatic inflammation in NAFLD/NASH
without the confounding effects of weight gain, adipose tissue
inflammation, and insulin resistance. Moreover, sEH is a
bifunctional enzyme with both an epoxide hydrolase and lipid
phosphatase domain [43]. Genetic disruption of sEH, which
abolishes both domains, has been reported to lower basal plasma
cholesterol levels [44]; however, in the present study genetic
disruption of sEH did not have an effect on the atherogenic diet
induced increase in plasma or hepatic cholesterol levels. There-
fore, it is unlikely that changes in cholesterol metabolism impacted
the anti-inflammatory phenotypes observed in the Ephx22/2 mice.
Follow-up studies evaluating the effects of Ephx2 disruption and
pharmacologic strategies that promote the effects of EETs,
including sEH inhibitors and stable EET analogs, in additional
models of NAFLD/NASH remain necessary to elucidate the
functional contribution of CYP-derived EETs to fatty liver disease.
Conclusions
In summary, we have demonstrated that hepatic CYP
epoxygenase activity, and hepatic and circulating EET levels, is
significantly and preferentially suppressed in the atherogenic diet
model of NAFLD/NASH. In addition, genetic disruption of sEH
increased EET levels and attenuated atherogenic diet induced
hepatic inflammation and injury. Collectively, these data suggest
that suppression of hepatic CYP-mediated EET biosynthesis is an
important pathological consequence of NAFLD/NASH, and
indicate that the CYP epoxygenase pathway is an important
regulator of the NAFLD/NASH-associated hepatic inflammatory
response in vivo. Future studies are needed to evaluate the
therapeutic utility of strategies that promote the effects of CYP-
derived EETs in NAFLD/NASH, and improve our understanding
of the mechanisms underlying the contribution of sEH and EETs
to the regulation of NAFLD/NASH-associated chronic hepatic
inflammation.
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